<DOC>
	<DOCNO>NCT00309179</DOCNO>
	<brief_summary>This study propose determine safety administration E7820 plus cetuximab explore MTD combination Phase Ib study . In addition , efficacy combination explore patient colorectal cancer Phase II proof concept phase study .</brief_summary>
	<brief_title>A Phase II Study Safety Efficacy E7820 Plus Cetuximab Colorectal Cancer , Preceded Run-in Study Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>For Phase Ib , patient must histologically cytologically confirm malignant solid tumor effective therapy available patient must candidate standard therapy . For Phase II , patient must pathologically histologically document colorectal carcinoma inoperable and/or metastatic . These patient must also least one unidimensional measurable lesion accord RECIST guideline . Patients must ECOG Performance Status 01 . Patients must life expectancy &gt; = 3 month . Patients must age &gt; = 18 year . Patients must adequate renal function evidence serum creatinine &lt; 2 mg/dL creatinine clearance &gt; 40 mL/minute . Patients must adequate bone marrow function evidence ANC &gt; = 1,500 /mm3 platelet &gt; = 100,000 /mm3 . Patients must adequate hepatic function evidence liver function test abnormality great CTC grade 1 ( bilirubin , alanine transaminase [ ALT ] , aspartate transaminase [ AST ] ) unless increase LFTs related liver metastasis case CTC grade 2 abnormality acceptable . Patients must willing able comply study protocol duration study . Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Patients may receive prior bevacizumab therapy long therapy discontinue 4 week longer . Patients history previous Grade 2 high hypersensitivity sulfonamide derivative . Patients previously treat cetuximab , receive prior treatment EGFRrelated cancer therapy , either approve investigational agent . Patients know sensitivity murine monoclonal antibody . Patients radiation &gt; = 25 % bone marrow ( e.g. , pelvic radiation ) within 4 week prior E7820 treatment . Patients recover clinically significant ( Grade 3 4 ) chemotherapy , immunotherapy , radiotherapy relate toxicity study entry ( exclude neuropathy , infertility , alopecia ) . Patients receive investigational drug antineoplastic therapy within 28 day E7820 treatment . Patients major surgery within 4 week study drug administration . Women pregnant breastfeeding . Women childbearing potential either positive pregnancy test screening pregnancy test . Women childbearing potential unless use adequate measure contraception opinion Investigator ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Fertile men fertile woman willing use contraception fertile men fertile woman partner willing use contraception . Patients brain subdural metastasis eligible except complete local therapy discontinue use corticosteroid indication least one month start treatment E7820 . Any sign ( eg , radiologic ) and/or symptom brain metastasis must stable least one month . Patients positive history human immunodeficiency virus , hepatitis B active hepatitis C. Patients severe uncontrolled intercurrent illness/infection ( exclude malignancy ) . Patients history unstable ischemic cardiac disease Class II NYHA heart failure . Patients history clinically significant arterial thrombosis take therapeutic dos anticoagulant within last 7 day . Patients pulmonary disease put risk hemoptysis bleed diathesis . Head neck cancer patient risk major vessel bleed . Patients receive therapeutic dose anticoagulant . Patients poorly control type I insulindependent diabetes poorlycontrolled type II insulindependent diabetes fast blood glucose &gt; 10 mmol/L ( 200 mg/dL ) . Patients significant comorbid disease condition , Investigator 's opinion would exclude patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced colorectal cancer</keyword>
</DOC>